Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 15Fallopian Tube Neoplasms 13Lung Neoplasms 11Melanoma 8Colorectal Neoplasms 8Glioblastoma 7Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Brain Neoplasms 4Rectal Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Oligodendroglioma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, B-Cell 2Lymphoma 2

Interventions

Nivolumab 5pembrolizumab 3avelumab 3Neoadjuvant Therapy 3toripalimab 2durvalumab 2atezolizumab 2Celecoxib 2spartalizumab 1relatlimab 1fludarabine phosphate 1fludarabine 1dostarlimab 1danvatirsen 1XELOX 1Surgical Procedures, Operative 1Oxaliplatin 1Leucovorin 1Ipilimumab 1Induction Chemotherapy 1Immunotherapy 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1IMM-101 1Fluorouracil 1Docetaxel 1Disulfides 1DEAE-Dextran 1Cyclophosphamide 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Turcot syndrome × Disulfides × Clear all
NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
39 enrolled
GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡